For centuries, individuals have used microdoses of psilocybin and peyote to alleviate physical discomfort and improve overall well-being. In contemporary practices, microdosing has expanded to include substances like MDMA, the prescription medication Ritalin, cannabis, and ketamine. While these substances can be hallucinogenic at higher doses, they do not produce psychedelic effects when taken in microdoses.

The classification of ketamine as a psychedelic has been a topic of debate within the scientific and medical communities. While ketamine does induce hallucinations and altered states of consciousness, it differs from classical psychedelics in its mechanism of action and phenomenological effects.

There are different types of neurotransmitters, and each one connects to a specific receptor within a cell membrane.

Not all neurotransmitters are the same. There are both inhibitory and excitatory neurotransmitters and they influence neurons in unique ways.

The medical community has understood the connection between glutamate and depression since the 90s, yet there were no drugs that made a significant impact on this area of the brain.

Once this process is underway, patients can see results quickly.